Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211245027> ?p ?o ?g. }
- W4211245027 abstract "Background Zuclopenthixol dihydrochloride, given orally, is commonly used for managing the signs and symptoms of schizophrenia. Objectives To determine the effects of zuclopenthixol dhydrochloride for treatment of schizophrenia. Search methods We searched the Cochrane Schizophrenia Group's register (December 2004). This register is compiled of methodical searches of BIOSIS, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings. To identify further trials we also contacted a pharmaceutical company and authors of relevant studies. We updated this search July 2012, 8 trials have been added to the awaiting assessment section. Selection criteria We included all randomised controlled trials comparing zuclopenthixol dihydrocodine with antipsychotics or with placebo (or no intervention) for treatment of schizophrenia and/or schizophrenia‐like psychoses. Data collection and analysis We independently inspected citations and abstracts, ordered papers, re‐inspected and quality assessed articles and extracted data. For dichotomous data we calculated relative risks (RR) and the 95% confidence intervals (CI) and the number needed to treat (NNT) or number needed to harm statistics. For continuous data we calculated weighted mean differences with 95% CIs for non‐skewed data. Main results We included eighteen trials involving 1578 people. Two trials compared zuclopenthixol with placebo and neither reported global or mental state outcomes. People allocated zuclopenthixol did have increased risk of experiencing extraparamydal symptoms compared with placebo (n=64, RR 5.37, CI 1.12 to 29.34 NNH 2 CI 2 to 31). Ten short trials (total n=478) compared zuclopenthixol with other typical antipsychotics. Risk of being unchanged or worse was decreased by allocation to zuclopenthixol (n=357, 7 RCTs, RR 0.72 CI 0.53 to 0.98, NNT 10 CI 6 to 131). No findings suggest any clear difference between zuclopenthixol and other typical antipsycotics across a whole range of adverse effects, including movement disorders (n=280, 6 RCTs, RR needing additional antiparkinsonian medication 1.07 CI 0.86 to 1.33) and general agitation (n=162, 3 RCTs, RR needing treatment with hypnotic/sedative drugs 1.09 CI 0.76 to 1.56). Fewer people allocated zuclopenthixol left in the short term compared with those given other typical antipsychotics (n=424, 22% vs 30%, 8 RCTs, RR 0.70 CI 0.51 to 0.95, NNT 12 CI 7 to 67). Three short trials (total n=233) compared zuclopenthixol with atypical antipsychotics. Zuclopenthixol was associated with no greater risk of being unchanged or worse compared with risperidone (n=98, 1 RCT, RR 1.30 CI 0.80 to 2.11). People allocated zuclopenthixol were prescribed antiparkinsonian medication more frequently compared to those treated with risperidone (n=98, 1 RCT, RR 1.92 CI 1.12 to 3.28, NNH 3 CI 3 to 17). Weight gain was equal for people allocated zuclopenthixol and those given sulpiride (n=61, 1 RCT, WMD 1.60 CI 8.35 to 5.15). Many people left these short studies early (45% zuclopenthixol vs 30% risperidone, n=159, 2 RCTs, RR 1.48 CI 0.98 to 2.22). The two isomers of zuclopenthixol, when compared in four short studies (total n=140), did not result in clearly different outcomes. Authors' conclusions There is an indication that zuclopenthixol causes movement disorders, perhaps more so than the newer generation of drugs, though no more frequently than the older generation of antipsychotics. There is some suggestion from this review that oral zuclopenthixol may have some clinical advantage, at least in the short term, over other older drugs in terms of global state. If an older drug is going to be prescribed, zuclopenthixol dihydrochloride is a viable option but may be best taken with additional medication to offset movement disorders that occur in about half the people taking this drug. There is no information on service, functional, behavioural outcomes and important outcomes such as relapse, for such a widely used drug this would indicate the need for further studies. We feel that it should remain a choice in the treatment of those for whom older generation drugs are indicated. Note: the 8 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed." @default.
- W4211245027 created "2022-02-13" @default.
- W4211245027 creator A5071626917 @default.
- W4211245027 creator A5082173751 @default.
- W4211245027 date "2005-10-19" @default.
- W4211245027 modified "2023-10-02" @default.
- W4211245027 title "Zuclopenthixol dihydrochloride for schizophrenia" @default.
- W4211245027 cites W1591259115 @default.
- W4211245027 cites W1893641096 @default.
- W4211245027 cites W1927380745 @default.
- W4211245027 cites W1970221328 @default.
- W4211245027 cites W1977185679 @default.
- W4211245027 cites W1977233625 @default.
- W4211245027 cites W1978040764 @default.
- W4211245027 cites W1978109763 @default.
- W4211245027 cites W1985749905 @default.
- W4211245027 cites W1991309148 @default.
- W4211245027 cites W1992249059 @default.
- W4211245027 cites W1994586716 @default.
- W4211245027 cites W1995568322 @default.
- W4211245027 cites W2002362645 @default.
- W4211245027 cites W2004088515 @default.
- W4211245027 cites W2004808174 @default.
- W4211245027 cites W2006529844 @default.
- W4211245027 cites W2015484208 @default.
- W4211245027 cites W2019441938 @default.
- W4211245027 cites W2020729534 @default.
- W4211245027 cites W2020844317 @default.
- W4211245027 cites W2022015574 @default.
- W4211245027 cites W2023839473 @default.
- W4211245027 cites W2025153028 @default.
- W4211245027 cites W2026799181 @default.
- W4211245027 cites W2030437868 @default.
- W4211245027 cites W2033976370 @default.
- W4211245027 cites W2036585786 @default.
- W4211245027 cites W2049984989 @default.
- W4211245027 cites W2058807740 @default.
- W4211245027 cites W2058874144 @default.
- W4211245027 cites W2062210283 @default.
- W4211245027 cites W2064703079 @default.
- W4211245027 cites W2067553692 @default.
- W4211245027 cites W2069024088 @default.
- W4211245027 cites W2077942878 @default.
- W4211245027 cites W2081826421 @default.
- W4211245027 cites W2085312153 @default.
- W4211245027 cites W2101299963 @default.
- W4211245027 cites W2109216757 @default.
- W4211245027 cites W2131823335 @default.
- W4211245027 cites W2135029321 @default.
- W4211245027 cites W2135057965 @default.
- W4211245027 cites W2140606211 @default.
- W4211245027 cites W2142960568 @default.
- W4211245027 cites W2147094685 @default.
- W4211245027 cites W2169918425 @default.
- W4211245027 cites W2199472295 @default.
- W4211245027 cites W2313861780 @default.
- W4211245027 cites W2405452595 @default.
- W4211245027 cites W2441296683 @default.
- W4211245027 cites W2471144606 @default.
- W4211245027 cites W4235467796 @default.
- W4211245027 cites W4238877299 @default.
- W4211245027 cites W4320288061 @default.
- W4211245027 doi "https://doi.org/10.1002/14651858.cd005474" @default.
- W4211245027 hasPublicationYear "2005" @default.
- W4211245027 type Work @default.
- W4211245027 citedByCount "7" @default.
- W4211245027 countsByYear W42112450272013 @default.
- W4211245027 countsByYear W42112450272015 @default.
- W4211245027 countsByYear W42112450272016 @default.
- W4211245027 countsByYear W42112450272017 @default.
- W4211245027 countsByYear W42112450272020 @default.
- W4211245027 crossrefType "journal-article" @default.
- W4211245027 hasAuthorship W4211245027A5071626917 @default.
- W4211245027 hasAuthorship W4211245027A5082173751 @default.
- W4211245027 hasConcept C118552586 @default.
- W4211245027 hasConcept C126322002 @default.
- W4211245027 hasConcept C142454548 @default.
- W4211245027 hasConcept C142724271 @default.
- W4211245027 hasConcept C168563851 @default.
- W4211245027 hasConcept C17744445 @default.
- W4211245027 hasConcept C187212893 @default.
- W4211245027 hasConcept C199539241 @default.
- W4211245027 hasConcept C204787440 @default.
- W4211245027 hasConcept C27081682 @default.
- W4211245027 hasConcept C27415008 @default.
- W4211245027 hasConcept C2776412080 @default.
- W4211245027 hasConcept C2779473830 @default.
- W4211245027 hasConcept C2779549880 @default.
- W4211245027 hasConcept C2781145037 @default.
- W4211245027 hasConcept C44249647 @default.
- W4211245027 hasConcept C67774102 @default.
- W4211245027 hasConcept C71924100 @default.
- W4211245027 hasConcept C82789193 @default.
- W4211245027 hasConcept C95190672 @default.
- W4211245027 hasConceptScore W4211245027C118552586 @default.
- W4211245027 hasConceptScore W4211245027C126322002 @default.
- W4211245027 hasConceptScore W4211245027C142454548 @default.
- W4211245027 hasConceptScore W4211245027C142724271 @default.
- W4211245027 hasConceptScore W4211245027C168563851 @default.
- W4211245027 hasConceptScore W4211245027C17744445 @default.